Standard Lithium Announces Closing of $21.6 million Bought Deal Private Placement of Units
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
VANCOUVER, British Columbia, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSX-V:SLL) (OTCQX:STLHF) (FRA:S5L) announced today that it has closed its previously announced bought deal private placement of 10,312,821 units of the Company (the "Units"), at a price of $2.10 per Unit, for aggregate gross proceeds to the Company of $21,656,924, including the issuance and sale of the Underwriters' (as defined below) option (the "Offering"). Each Unit consists of one common share of the Company and one-half of one common share purchase warrant (each whole common share purchase warrant, a "Warrant"). Each Warrant is exercisable to acquire one common share of the Company (a "Warrant Share") until February 16, 2020 at an exercise price of $2.60 per Warrant Share, subject to adjustment in certain events. Net proceeds from the Offering will be used for exploration and development activities on the Company's properties and for general corporate purposes.
The Offering was conducted by a syndicate of underwriters led by Canaccord Genuity Corp., as sole bookrunner and lead underwriter, and including GMP Securities L.P. (the "Underwriters"). In connection with completion of the Offering, the Underwriters received a cash commission of 7.0% and options to acquire a number of Units equal to 7.0% of the Units issued in the Offering until February 16, 2020 at an exercise price of $2.10. The Company paid a further cash commission of 3.0% and issued common shares equal to 3.0% of the Units issued in the Offering to a third-party who assisted in facilitating the Offering.
All securities issued or issuable under the Offering are subject to a statutory hold period lasting four months and one day following the closing of the Offering.
About Standard Lithium Ltd.
Standard Lithium's value creation strategy encompasses acquiring a diverse and highly prospective portfolio of large-scale domestic brine resources, led by an innovative and results-oriented management team with a strong focus on technical skills. The Company is currently focused on the immediate exploration and development of the Bristol Dry Lake Lithium Project located in the Mojave region of San Bernardino County, California; the location has significant infrastructure in-place, with easy road and rail access, abundant electricity and water sources, and is already permitted for extensive brine extraction and processing activities. The Company is also commencing resource evaluation on up to approximately 33,000 acres of brine leases located in the Smackover Formation.
Standard Lithium is listed on the TSX Venture under the trading symbol "SLL"; quoted on the OTCQX under the symbol "STLHF"; and on the Frankfurt Stock Exchange under the symbol "S5L". Please visit the Company's website at www.standardlithium.com.
For further information, contact Anthony Alvaro at (604) 240 4793.
On behalf of the Board,
Standard Lithium Ltd.
Robert Mintak, CEO & Director
The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may contain certain "Forward-Looking Statements" within the meaning of applicable Canadian securities laws. When used in this news release, the words "anticipate", "believe", "estimate", "expect", "target, "plan", "forecast", "may", "schedule" and other similar words or expressions identify forward-looking statements or information. These forward-looking statements or information may relate to the anticipated use of proceeds of the Offering, future prices of commodities, accuracy of mineral or resource exploration activity, reserves or resources, regulatory or government requirements or approvals, the reliability of third party information, continued access to mineral properties or infrastructure, fluctuations in the market for lithium and its derivatives, changes in exploration costs and government regulation in Canada and the United States, and other factors or information. Such statements represent the Company's current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Many factors, both known and unknown, could cause results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affecting such statements and information other than as required by applicable laws, rules and regulations.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Standard Lithium Ltd. via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Nampala Project (Mali): Exploration Program Started in 2017 to be Double Based on Promising and Encouraging New Mineral Resource Estimate and Supported by Well-oriented Geology24.9.2018 14:30 | Pressemelding
QUÉBEC CITY, Quebec, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Robex Resources Inc. (« Robex » and/or « the Company ») (TSXV : RBX / FWB : RB4) is pleased to report to the market the integration of all its 2017-2018 drilling results in a new Mineral Resource estimate in accordance with National Instrument 43-101 and resumption of its exploration and drilling works on its Nampala gold project (Nampala and Mininko properties, Mali). 2017-2018 DRILLING AND NEW MINERAL RESOURCE ESTIMATE (MRE 2018) HIGHLIGHTS 1 Main highlights are: Indicated Mineral Resources totaling 242,000 ounces of gold (175,000 oz in saprolite type (oxides), 61,000 oz in transition zone and 6,000 oz in fresh rock (sulphides)), which corresponds to a total of 10,148,000 t at 0.74 g/t Au; Inferred Mineral Resources totaling 81,000 ounces of gold (61,000 oz in saprolite type (oxides), 16,000 oz in transition zone and 4,000 oz in fresh rock (sulphides)), which corresponds to a total of 3,429,000 t at 0.73 g/t Au; Impact positif 2
XBiotech Announces Completion of U.S. Enrollment in Phase 2 Multicenter Study Evaluating Bermekimab in Patients with Hidradenitis Suppurativa24.9.2018 14:30 | Pressemelding
AUSTIN, Texas, Sept. 24, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that it had completed enrollment in the U.S. for its Phase 2, open label clinical study evaluating subcutaneous administration of bermekimab in patients with moderate to severe Hidradenitis Suppurativa (HS). Enrollment has exceeded the planned limit for the study in just over two months, significantly outpacing expectations. XBiotech plans to accept a limited number of additional patients in Europe prior to study completion. John Simard, Chairman & CEO of XBiotech, commented, “We are very pleased by the enrollment rate we have seen in this study. Patient availability has been well beyond what was predicted. I believe this speaks to the need for new treatment options for this debilitating disease. I want to thank all of the patients and clinical sites for their ongoing participation in this study.” The phase 2 study involves a 13-week treatment regimen. Two groups of patients are being treated
ILPA Publishes Diversity and Inclusion Resources for the Private Equity Industry24.9.2018 13:00 | Pressemelding
Expansion to the ILPA Standard DDQ and Guidance on Code of Conduct Seek to Advance D&I Efforts Across the Ecosystem WASHINGTON and TORONTO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- The Institutional Limited Partners Association (ILPA) today announced the publication of several resources developed to support the advancement of diversity and inclusion (D&I) within the private equity (PE) industry. These resources include an expansion to ILPA’s standard Due Diligence Questionnaire (DDQ) and guidance for developing organizational Codes of Conduct for general partners (GPs), limited partners (LPs) and fund portfolio companies. The work was completed over the course of 2018 by a cross section of ILPA members representing a global perspective. Steve Nelson, CEO of ILPA, reflected on the imperative for all industry players to contribute to the D&I effort in a positive manner: “ILPA believes that diversity and inclusion is a strength that all stakeholders within the private equity ecosystem should em
SolarWinds to Showcase Change Monitoring and Extended Azure Monitoring Capabilities Across Unified Infrastructure Management and SaaS solutions Portfolio at Microsoft Ignite 201824.9.2018 12:30 | Pressemelding
Highlights support for IT Professionals and DevOps teams operating on and across Microsoft on-premise environments, Microsoft Azure, and Office 365 AUSTIN, Texas, Sept. 24, 2018 (GLOBE NEWSWIRE) -- SolarWinds, a leading provider of powerful and affordable IT management software, today announced its participation at Microsoft Ignite® 2018, September 24-28, 2018, in Orlando, Florida. SolarWinds will demonstrate the latest updates to its unified infrastructure management portfolio, built on the SolarWinds® Orion® Platform, alongside its suite of SaaS-delivered products designed for DevOps teams. These portfolio enhancements are designed to deepen visibility across both cloud infrastructure and applications to simplify full-stack monitoring for DevOps and IT professionals. The company will also preview its upcoming Cost Calculator for Microsoft® Azure® free tool. “Optimizing performance across even the most complex environments can be accomplished,” said Christoph Pfister, executive vice p
Barefoot Networks Teams Up with Western Digital and Università della Svizzera italiana to Showcase In-Network Consensus for Use with Storage Class Memory and P424.9.2018 09:00 | Pressemelding
Barefoot Tofino™ Used in P4 Implementation for Low Latency Storage Class Memory Access is Presented at the P4 European Workshop CAMBRIDGE, United Kingdom, Sept. 24, 2018 (GLOBE NEWSWIRE) -- P4 European Workshop —At the P4 European Workshop (P4EU 2018), Barefoot Networks and researchers from Western Digital and Università della Svizzera italiana (USI), with support from Xilinx and STORDIS, will today present a new breakthrough for providing in-network high-performance fault tolerance for Storage Class Memory (SCM) access using the P4 programming language. The demonstration uses a P4 program implementation developed by Western Digital and USI using Barefoot’s 6.5Tb/s Tofino™ switch ASIC. Programmable forwarding plane technology is enabling network owners to create and deliver value by accelerating application performance. One of the ways this is achieved is by offloading network functions that are run on servers or appliances onto switches. In addition to performing all standard switch a
4D Announces Positive Data From Phase 1b Study of Thetanix in Paediatric Crohn's Diseases Patients and Publication of Studies Showing Strong Efficacy of Thetanix in Preclinical Models of IBD24.9.2018 08:00 | Pressemelding
LEEDS, United Kingdom, Sept. 24, 2018 (GLOBE NEWSWIRE) -- 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutics, today announces positive top-line results for its Phase 1b study of Thetanix in paediatric patients with Crohn’s disease. The study achieved its primary objective, demonstrating that Thetanix was well tolerated with a good safety profile. The randomised, double-blind, placebo-controlled study was conducted in two parts, with a single-dose phase and a multiple-dose phase and treated a total of 18 subjects aged 16-18 with Crohn’s disease. In the single-dose phase, eight subjects were given a single dose of either Thetanix or placebo. In the multiple-dose phase, 10 subjects were given either Thetanix or placebo twice daily for seven consecutive days. The Company also announces the publication of data demonstrating the efficacy of Thetanix in pre-clinical models of inflammatory bowel disease (IBD). The data, published in the journal
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom